A sigh of relief for migraineurs, the US FDA has recently approved Fremanezumab preventive treatment of migraine among adults. Migraine is one of the primary cause of disability that causes a severe headache with photophobia, phonophobia, nausea and vomiting. Fremanezumab is a fully humanized monoclonal antibody that mainly targets the calcitonin gene-related peptide, a vasodilatory neuropeptide associated with the migraine pathophysiology. In a report of the multinational, phase III studies, Fremanezumab significantly decreases the requirement for acute headache medication use, headache-related disability, and migraine incidence as compared to the placebo.

A phase II development for the preventive treatment of post-traumatic headache disorder and phase III development for the preventive treatment of cluster headache analysis of Fremanezumab is also under process. A regulatory evaluation for Fremanezumab as preventive therapy of migraine among adults is also initiated in the EU. With all these trials, Fremanezumab is on the way to becoming a first global approval medication for migraine prevention.